Tags

Type your tag names separated by a space and hit enter

Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles.

Abstract

Recent establishment of a sensitive ELISA system using antibodies against malondialdehyde-modified low density lipoprotein (MDA-LDL) made it possible to determine the circulating oxidized lipoprotein levels. Here, we investigated the serum levels of MDA-LDL in 62 patients with coronary artery disease (CAD) compared with the levels in 42 patients without CAD [groups CAD(+) and CAD(-), respectively], which are adjusted for age, serum total cholesterol, LDL and high density lipoprotein cholesterol, and triglyceride levels. Serum MDA-LDL levels were 113.4+/-49.1 IU/L in CAD(+), which were significantly higher than the levels in CAD(-) (85.2+/-22.5 IU/L, P<0.0005). The ratio of MDA-LDL/LDL cholesterol was 0.95+/-0.32 in CAD(+), indicating a significant increase compared with the ratio in CAD(-) (0.68+/-0.19, P<0.0005). The positive correlation of MDA-LDL level and the ratio of MDA-LDL/LDL cholesterol with intima-media thickness in carotid arteries was observed. Age was not clearly associated with the MDA-LDL level (P=0.865). The serum MDA level was positively correlated with LDL cholesterol (P<0.0001) and with triglycerides (P<0.001) and negatively correlated with high density lipoprotein cholesterol (P<0.05). Furthermore, the MDA-LDL level was negatively correlated with the peak size of the LDL particle (P<0.01). The LDL subclasses that were identified by using the sera collected from the subjects by sequential ultracentrifugation showed that the ratios of MDA-LDL/apolipoprotein B in LDL3 and LDL4 were nearly 3-fold higher than those in LDL1 and LDL2 for CAD(+) and CAD(-). These results indicate that the circulating MDA-LDL level is increased in CAD(+), independent of the serum LDL cholesterol level but in association with the peak size of LDL particles. The measurement of serum MDA-LDL level may be useful for the identification of patients with advanced atherosclerosis.

Links

  • Aggregator Full Text
  • Authors+Show Affiliations

    ,

    Department of Clinical Cell Biology, M6, Chiba University Graduate School of Medicine, Chiba.

    , , , , , ,

    Source

    MeSH

    Aged
    Biomarkers
    Carotid Artery Diseases
    Case-Control Studies
    Cholesterol
    Cholesterol, HDL
    Cholesterol, LDL
    Coronary Disease
    Endothelium, Vascular
    Enzyme-Linked Immunosorbent Assay
    Female
    Humans
    Lipoproteins, LDL
    Male
    Malondialdehyde
    Middle Aged
    Oxidation-Reduction
    Triglycerides

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    11950707

    Citation

    Tanaga, Kosei, et al. "Increased Circulating Malondialdehyde-modified LDL Levels in Patients With Coronary Artery Diseases and Their Association With Peak Sizes of LDL Particles." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 4, 2002, pp. 662-6.
    Tanaga K, Bujo H, Inoue M, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol. 2002;22(4):662-6.
    Tanaga, K., Bujo, H., Inoue, M., Mikami, K., Kotani, K., Takahashi, K., ... Saito, Y. (2002). Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arteriosclerosis, Thrombosis, and Vascular Biology, 22(4), pp. 662-6.
    Tanaga K, et al. Increased Circulating Malondialdehyde-modified LDL Levels in Patients With Coronary Artery Diseases and Their Association With Peak Sizes of LDL Particles. Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):662-6. PubMed PMID: 11950707.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. AU - Tanaga,Kosei, AU - Bujo,Hideaki, AU - Inoue,Masahiro, AU - Mikami,Keiji, AU - Kotani,Kazuo, AU - Takahashi,Kazuo, AU - Kanno,Takashi, AU - Saito,Yasushi, PY - 2002/4/16/pubmed PY - 2002/5/7/medline PY - 2002/4/16/entrez SP - 662 EP - 6 JF - Arteriosclerosis, thrombosis, and vascular biology JO - Arterioscler. Thromb. Vasc. Biol. VL - 22 IS - 4 N2 - Recent establishment of a sensitive ELISA system using antibodies against malondialdehyde-modified low density lipoprotein (MDA-LDL) made it possible to determine the circulating oxidized lipoprotein levels. Here, we investigated the serum levels of MDA-LDL in 62 patients with coronary artery disease (CAD) compared with the levels in 42 patients without CAD [groups CAD(+) and CAD(-), respectively], which are adjusted for age, serum total cholesterol, LDL and high density lipoprotein cholesterol, and triglyceride levels. Serum MDA-LDL levels were 113.4+/-49.1 IU/L in CAD(+), which were significantly higher than the levels in CAD(-) (85.2+/-22.5 IU/L, P<0.0005). The ratio of MDA-LDL/LDL cholesterol was 0.95+/-0.32 in CAD(+), indicating a significant increase compared with the ratio in CAD(-) (0.68+/-0.19, P<0.0005). The positive correlation of MDA-LDL level and the ratio of MDA-LDL/LDL cholesterol with intima-media thickness in carotid arteries was observed. Age was not clearly associated with the MDA-LDL level (P=0.865). The serum MDA level was positively correlated with LDL cholesterol (P<0.0001) and with triglycerides (P<0.001) and negatively correlated with high density lipoprotein cholesterol (P<0.05). Furthermore, the MDA-LDL level was negatively correlated with the peak size of the LDL particle (P<0.01). The LDL subclasses that were identified by using the sera collected from the subjects by sequential ultracentrifugation showed that the ratios of MDA-LDL/apolipoprotein B in LDL3 and LDL4 were nearly 3-fold higher than those in LDL1 and LDL2 for CAD(+) and CAD(-). These results indicate that the circulating MDA-LDL level is increased in CAD(+), independent of the serum LDL cholesterol level but in association with the peak size of LDL particles. The measurement of serum MDA-LDL level may be useful for the identification of patients with advanced atherosclerosis. SN - 1524-4636 UR - https://www.unboundmedicine.com/medline/citation/11950707/Increased_circulating_malondialdehyde_modified_LDL_levels_in_patients_with_coronary_artery_diseases_and_their_association_with_peak_sizes_of_LDL_particles_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=11950707.ui DB - PRIME DP - Unbound Medicine ER -